Eric N. Momin, Ahmed Mohyeldin, Hasan A. Zaidi, Guillermo Vela and Alfredo Quinones-Hinojosa Pages 326 - 344 ( 19 )
Cellular therapies represent a new frontier in the treatment of neurological disease. Mesenchymal stem cells (MSCs), which can be harvested from bone marrow, adipose tissue, and umbilical cord blood, among many other sources, possess several qualities which may be used to treat diseases of the central nervous system. MSCs migrate to sites of malignancy, a property which may be used for the treatment of brain cancer. MSCs possess immunosuppressive properties, which may be used for the treatment of neurological disorders with an inflammatory etiology. Finally, MSCs restore injured neural tissue, a property which may be used for the treatment of neural injury. Approximately 23 clinical trials have been completed to date, with many more ongoing, and all have been listed in this review. The long-term safety of MSC-based therapies is not well established, and continues to be one major limitation to clinical translation. More broadly, only a small minority of clinical trials have employed rigorous designs that include prospective randomization, patients from multiple centers, clinically-relevant and reproducible endpoints, and adequate long-term follow-up. These limitations must be addressed before MSCs can enter widespread clinical use. Nevertheless, MSCs represent a promising new approach to treating diseases of the central nervous system that are traditionally associated with morbid outcomes. With additional pre-clinical and clinical studies that focus on their potential benefits as well as dangers, MSCs may one day find translation to clinical use in the setting of neurological disease.
Mesenchymal stem cells, brain neoplasms, nervous system diseases, Parkinson disease, stroke, clinical trial, cell transplantation, Treatment of Neurological Diseases, Alzheimer disease, clinical applications, central nervous system, osteocytic, chondrocytic, adipogenic, migration toward cancer, restoration of injured tissue, Plastic-adherence, nological cells, colony-forming unit fibroblasts, marrow stromal cells, multiple cell types, osteoblasts, fibroblasts, glands, periodontal ligament, umbilical cord blood, HARVESTING MESENCHYMAL STEM CELLS, adipose tissue, liposuction, morbidity, mortality, brain cancer, neurosurgical procedures, non-adherent cells, placenta, mononuclear cells, chondrocytes, gastrointestinal inflammation, Helicobacter pylori, Lewis lung carcinoma, melanoma lung metastasis models, metastasis, Tumor Growth, implantation of Renca adenocarcinoma, angiogenesis, inflammatory component, allogeneic donors, T Lymphocytes, proliferation, isoform of the human leukocyte, maternal tolerance, T-regulatory cells, interferon, B Lymphocytes, chemotactic potential, ligands, Dendritic Cells, pathogenic material, Natural Killer Cells, Neutrophils, adhesion molecules, cytotoxic effect, defensive mechanisms, NEURODEGENERATIVE DISORDERS, Amyotrophic Lateral Sclerosis, basal forbrain, excitioxocity, amyloid formation, forebrain cholinergic neurons, TREATMENT OF ISCHEMIC NEURAL INJURY, postmortem brain, Treatment of Stroke, ipsilateral carotid artery, non-ischemic hemisphere, chromosomal anomalies, biosafety, myocardial infarction, graft-versus-host disease, insertional mutagenesis
Brain Tumor Stem Cell&Neuro-Oncology Surgical Outcomes Laboratory, Department of Neurosurgery and Oncology, 1550 Orleans Street, Cancer Research Building II Room 253, Baltimore, MD 21231, USA.